What is the most recent earnings date for FDMT stock?
4D MOLECULAR THERAPEUTICS IN (FDMT) last reported earnings on 2/27/2026.
4D MOLECULAR THERAPEUTICS IN (FDMT) Earnings History & Surprises
NASDAQ:FDMT • US35104E1001
Current stock price
8.61 USD
-0.37 (-4.12%)
At close:
8.61 USD
0 (0%)
After Hours:
FDMT Earnings overview
Past quarterly earnings results for 4D MOLECULAR THERAPEUTICS IN (FDMT), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 6, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.78
- Revenue Estimate
- 9.364M
Last Reported
Most Recent- Release Date
- Feb 27, 2026
- Period
- Q3 / 2025
- EPS Reported
- -$1.01
- EPS Surprise
- -1.18%
- Revenue Surprise
- -69.35%
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -1.01 | -1.00 | -1.18% | -27.85% | 90K | 293.617K | -69.35% | 2,900.00% |
| Q2 2025 | -0.98 | -0.89 | -9.71% | -55.56% | 15K | 381.623K | -96.07% | 200.00% |
| Q1 2025 | -0.86 | -0.88 | 2.21% | -30.30% | 14K | 390.221K | -96.41% | -50.00% |
| Q4 2024 | -0.90 | -0.83 | -7.88% | -20.00% | 1K | 1.747M | -99.94% | -100.00% |
| Q3 2024 | -0.79 | -0.72 | -10.47% | -229.17% | 3K | 569.456K | -99.47% | -99.99% |
| Q2 2024 | -0.63 | -0.72 | 12.21% | 18.18% | 5K | 1.337M | -99.63% | -97.91% |
| Q1 2024 | -0.66 | -0.76 | 13.06% | 25.00% | 28K | 800.7K | -96.50% | -90.60% |
| Q4 2023 | -0.75 | -0.76 | 0.80% | 10.71% | 20.723M | 2.104M | 884.93% | 1,557.84% |
| Q3 2023 | -0.24 | -0.61 | 60.37% | 69.62% | 20.204M | 8.19M | 146.69% | 3,940.80% |
| Q2 2023 | -0.77 | -0.82 | 6.57% | 11.49% | 239K | 865.297K | -72.38% | 49.38% |
| Q1 2023 | -0.88 | -0.91 | 3.50% | -7.32% | 298K | 1.049M | -71.59% | -75.57% |
| Q4 2022 | -0.84 | -0.80 | -4.77% | 1.18% | 1.25M | 3.066M | -59.23% | 1,288.89% |
| Q3 2022 | -0.79 | -0.93 | 15.12% | 3.66% | 500K | 893.775K | -44.06% | -63.50% |
| Q2 2022 | -0.87 | -0.87 | -0.35% | -210.71% | 160K | 873.12K | -81.67% | -98.90% |
| Q1 2022 | -0.82 | -0.83 | 0.75% | -34.43% | 1.22M | 775.2K | 57.38% | -39.00% |
| Q4 2021 | -0.85 | -0.88 | 3.10% | 63.98% | 90K | 918K | -90.20% | 109.18% |
| Q3 2021 | -0.82 | -0.82 | 0.13% | - | 1.37M | 178.5K | 667.51% | -90.61% |
| Q2 2021 | -0.28 | -0.69 | 59.63% | - | 14.58M | 601.8K | 2,322.73% | - |
| Q1 2021 | -0.61 | -1.12 | 45.63% | - | 2M | - | - | |
| Q4 2020 | -2.36 | -0.67 | -250.56% | - | -980K | - | - | |
| Q3 2020 | - | - | 14.589M | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
1
Average EPS beat (4)
-4.14%
Max EPS beat (4)
2.21%
Min EPS beat (4)
-9.71%
Revenue beat statistics
Revenue beat (4)
0
Average Revenue beat (4)
-90.44%
Max Revenue beat (4)
-69.35%
Min Revenue beat (4)
-99.94%
Analysis
In the last 4 quarters, FDMT has beaten EPS estimates in 1 out of 4 releases
FDMT has not beaten revenue estimates in any of the last 4 earnings releases
In the last 4 quarters, FDMT reported -4.1% below the EPS estimates on average.
In the last 4 quarters, FDMT reported -90.4% below the revenue estimates on average.
Related analysis
4D MOLECULAR THERAPEUTICS IN / FDMT Earnings FAQ
Did 4D MOLECULAR THERAPEUTICS IN (FDMT) beat earnings estimates last quarter?
4D MOLECULAR THERAPEUTICS IN (FDMT) missed EPS estimates and missed revenue estimates in the most recent quarter.
How often does 4D MOLECULAR THERAPEUTICS IN (FDMT) beat earnings estimates?
In the last 4 quarters, 4D MOLECULAR THERAPEUTICS IN (FDMT) has beaten EPS estimates in 1 out of 4 releases.